Market Price

21.66 

-0.19 -0.9%

as of Mar 20 '19

52 Week Range:

12.73 32.19


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry and Serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and cattle, swine, poultry, horses, and aquacultured fish. Additionally, the company provides point-of-care testing diagnostic products for infectious diseases comprising influenza, streptococcus, etc., as well as acute myocardial infarction; diagnostics to measure bone and calcium metabolism markers, and drug concentration levels in the blood; high sensitivity products combining small immunofluorescence analyzers and special reagents; and authorized generic pharmaceuticals. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi, Ltd., as well as a joint development agreement with SanBio, Inc. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 5.08
6.22
6.94
6.94
7.26
6.85
7.16
8.76
9.25
9.98
9.89
growth rate 22.4% 11.6% 0.0% 4.6% -5.7% 4.5% 22.4% 5.6% 7.9% -0.9%
Earnings BIT 42,143.00
23,276.00
36,930.00
52,759.00
82,718.00
growth rate -44.8% 58.7% 42.9% 56.8%
Avg.PE 23.36
13.34
13.02
growth rate -42.9% -2.4%
ROA 6.54
5.05
4.12
2.76
1.50
1.72
3.17
2.25
3.48
3.86
6.67
growth rate -22.8% -18.4% -33.0% -45.7% 14.7% 84.3% -29.0% 54.7% 10.9% 72.8%
ROE 8.21
6.22
6.28
5.03
2.68
3.00
5.37
3.64
5.50
6.39
11.70
growth rate -24.2% 1.0% -19.9% -46.7% 11.9% 79.0% -32.2% 51.1% 16.2% 83.1%
ROIC 8.08
6.01
5.09
3.29
1.99
2.29
4.27
3.04
4.81
5.64
11.09
growth rate -25.6% -15.3% -35.4% -39.5% 15.1% 86.5% -28.8% 58.2% 17.3% 96.6%
Cur. Ratio 3.70
4.94
1.09
2.12
3.15
2.67
2.74
2.56
2.35
1.65
1.65
growth rate 33.5% -77.9% 94.5% 48.6% -15.2% 2.6% -6.6% -8.2% -29.8% 0.0%
Quick Ratio 2.13
3.49
0.69
1.52
2.26
1.90
1.97
1.87
1.62
1.02
1.35
growth rate 63.9% -80.2% 120.3% 48.7% -15.9% 3.7% -5.1% -13.4% -37.0% 32.4%
Leverage 1.26
1.21
1.82
1.82
1.75
1.74
1.65
1.58
1.59
1.72
1.79
growth rate -4.0% 50.4% 0.0% -3.9% -0.6% -5.2% -4.2% 0.6% 8.2% 4.1%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 131,478.00
154,170.00
151,999.00
155,587.00
127,659.00
113,401.00
growth rate 17.3% -1.4% 2.4% -18.0% -11.2%
Acct.Payable 14,253.00
43,884.00
12,492.00
12,153.00
14,514.00
58,708.00
growth rate 207.9% -71.5% -2.7% 19.4% 304.5%
Cur.Assets 333,438.00
359,612.00
401,699.00
421,584.00
376,454.00
348,581.00
growth rate 7.9% 11.7% 5.0% -10.7% -7.4%
Total Assets 607,219.00
659,033.00
711,583.00
707,715.00
793,950.00
809,684.00
growth rate 8.5% 8.0% -0.5% 12.2% 2.0%
Cash 18,753.00
22,299.00
30,553.00
54,922.00
71,408.00
147,775.00
growth rate 18.9% 37.0% 79.8% 30.0% 106.9%
Inventory 62,689.00
59,143.00
62,387.00
59,587.00
68,806.00
60,169.00
growth rate -5.7% 5.5% -4.5% 15.5% -12.6%
Cur.Liabilities 124,831.00
131,208.00
156,843.00
179,722.00
228,447.00
210,248.00
growth rate 5.1% 19.5% 14.6% 27.1% -8.0%
Liabilities 257,972.00
260,493.00
260,562.00
261,243.00
333,294.00
356,961.00
growth rate 1.0% 0.0% 0.3% 27.6% 7.1%
LT Debt 95,000.00
85,000.00
50,000.00
28,000.00
10,000.00
30,940.00
growth rate -10.5% -41.2% -44.0% -64.3% 209.4%
Equity 398,540.00
451,021.00
446,472.00
460,656.00
452,723.00
growth rate 13.2% -1.0% 3.2% -1.7%
Common Shares 397.00
397.00
397.00
397.00
397.00
397.00
397.00
397.00
397.00
397.00
397.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 7,817.00
10,332.00
8,662.00
5,382.00
8,132.00
5,129.00
growth rate 32.2% -16.2% -37.9% 51.1% -36.9%
Cash Dividends 7,152.00
7,152.00
7,152.00
7,151.00
7,944.00
growth rate 0.0% 0.0% 0.0% 11.1%
Cash From OA 49,914.00
49,943.00
30,251.00
49,415.00
21,624.00
93,420.00
growth rate 0.1% -39.4% 63.4% -56.2% 332.0%
FCF per Share 0.37
0.18
0.41
0.98
1.13
0.74
0.49
0.60
0.21
0.85
0.80
growth rate -51.4% 127.8% 139.0% 15.3% -34.5% -33.8% 22.5% -65.0% 304.8% -5.9%
FCF 22,865.00
9,459.00
20,553.00
45,895.00
39,531.00
39,889.00
28,387.00
17,885.00
39,675.00
8,165.00
81,066.00
growth rate -58.6% 117.3% 123.3% -13.9% 0.9% -28.8% -37.0% 121.8% -79.4% 892.9%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 347,724.00
387,693.00
371,370.00
403,206.00
411,638.00
466,838.00
growth rate 11.5% -4.2% 8.6% 2.1% 13.4%
Op.Income 10,043.00
42,143.00
23,276.00
36,930.00
52,759.00
82,718.00
growth rate 319.6% -44.8% 58.7% 42.9% 56.8%
IBT 34,709.00
33,754.00
39,560.00
47,217.00
84,866.00
growth rate -2.8% 17.2% 19.4% 79.7%
Net Income 10,043.00
20,061.00
15,447.00
24,697.00
28,991.00
53,448.00
growth rate 99.8% -23.0% 59.9% 17.4% 84.4%
EPS 64.39
50.30
52.75
42.27
21.72
25.28
50.49
38.88
62.16
78.82
134.53
growth rate -21.9% 4.9% -19.9% -48.6% 16.4% 99.7% -23.0% 59.9% 26.8% 70.7%
Gross Profit 246,038.00
283,593.00
270,143.00
298,735.00
311,567.00
354,493.00
growth rate 15.3% -4.7% 10.6% 4.3% 13.8%
R&D 69,804.00
71,304.00
82,033.00
80,819.00
86,928.00
growth rate 2.2% 15.1% -1.5% 7.6%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 8,699.00
26,774.00
15,814.00
13,793.00
17,224.00
growth rate 207.8% -40.9% -12.8% 24.9%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 139,699.00
113,401.00
121,326.00
120,071.00
121,999.00
growth rate -18.8% 7.0% -1.0% 1.6%
Acct.Payable 14,458.00
58,708.00
52,841.00
49,250.00
52,013.00
growth rate 306.1% -10.0% -6.8% 5.6%
Cur.Assets 407,099.00
348,581.00
348,524.00
348,990.00
348,157.00
growth rate -14.4% 0.0% 0.1% -0.2%
Total Assets 841,811.00
809,684.00
820,240.00
836,435.00
830,065.00
growth rate -3.8% 1.3% 2.0% -0.8%
Cash 104,412.00
147,775.00
138,944.00
137,585.00
139,559.00
growth rate 41.5% -6.0% -1.0% 1.4%
Inventory 65,282.00
60,169.00
65,343.00
68,508.00
64,987.00
growth rate -7.8% 8.6% 4.8% -5.1%
Cur.Liabilities 205,862.00
210,248.00
201,458.00
191,293.00
182,805.00
growth rate 2.1% -4.2% -5.1% -4.4%
Liabilities 325,186.00
356,961.00
352,426.00
345,334.00
332,062.00
growth rate 9.8% -1.3% -2.0% -3.8%
LT Debt 31,000.00
30,940.00
30,200.00
29,460.00
28,720.00
growth rate -0.2% -2.4% -2.5% -2.5%
Equity 516,625.00
452,723.00
467,814.00
491,101.00
498,003.00
growth rate -12.4% 3.3% 5.0% 1.4%
Common Shares 22,400.00
22,400.00
22,400.00
22,400.00
22,400.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 2,190.00
2,190.00
2,190.00
3,543.00
2,012.00
growth rate 0.0% 0.0% 61.8% -43.2%
Cash Dividends 7,451.00
7,451.00
7,451.00
95.00
3,568.00
growth rate 0.0% 0.0% -98.7% 3,655.8%
Cash From OA -8,492.00
-8,492.00
-8,492.00
15,453.00
12,190.00
growth rate 0.0% 0.0% 100.0% -21.1%
FCF -10,682.00
-10,682.00
-10,682.00
11,910.00
10,178.00
growth rate 0.0% 0.0% 100.0% -14.5%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 123,658.00
102,717.00
115,911.00
110,244.00
120,716.00
growth rate -16.9% 12.9% -4.9% 9.5%
Op.Income 8,699.00
26,774.00
15,814.00
13,793.00
17,224.00
growth rate 207.8% -40.9% -12.8% 24.9%
IBT 7,656.00
28,816.00
20,631.00
16,968.00
15,563.00
growth rate 276.4% -28.4% -17.8% -8.3%
Net Income 15,704.00
2,857.00
15,247.00
12,622.00
12,100.00
growth rate -81.8% 433.7% -17.2% -4.1%
Gross Profit 91,007.00
83,542.00
86,999.00
83,563.00
91,128.00
growth rate -8.2% 4.1% -4.0% 9.1%
R&D 27,521.00
19,025.00
20,864.00
20,458.00
20,647.00
growth rate -30.9% 9.7% -2.0% 0.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (66.20)

YOY Growth Grade:

E (27.26)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 21.16 20.41
EPS / Growth 1.06

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 0.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.6% 0.6% 0.6%
Future PE 0.01 0.60 0.60
Future EPS 1.13 1.13 1.13
Value Price
MOS %
0.00
-100.0%
0.17
-99.2%
0.17
-99.2%
MOS Price 0.00 0.08 0.08
IRT 19.22 19.22 19.22

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.